Median Percent Change From Baseline in Serum Concentrations of Circulating Biomarkers
| Sarilumab 200 mg q2w (N=153) | Adalimumab 40 mg q2w (N=154) | ||
|---|---|---|---|
| CRP | Wk 12 | -94.2† | -29.7 |
| Wk 24 | -94.0† | -24.0 | |
| SAA | Wk 12 | -79.9† | -32.2 |
| Wk 24 | -83.2† | -17.4 | |
| RANKL | Wk 2 | -2.5† | 4.4 |
| Wk 24 | -18.3† | 10.5 | |
| OPG | Wk 2 | 0.9* | -4.0 |
| Wk 24 | 2.2 | 3.3 | |
| Lp(a) | Wk 12 | -35.0† | -0.4 |
| Wk 24 | -41.0† | -2.8 | |
*Adjusted P<0.01 vs adalimumab. †Adjusted P<0.0001 vs adalimumab.